Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NEO-IMPACT : Investigating the safety and efficacy of NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer, NEO-IMPACT.

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Pancreas<br/>CancersCancer LocationPancreas

Systemic therapy | Stomach and upper gastrointestinal tractPancreas

Trial Overview Read MoreRead more

This phase II study is trying to understand how safe and effective combining standard chemotherapy (mFOLFIRINOX) with immunotherapy (durvalumab) is in people with early stage pancreatic cancer who are considered suitable for surgery.

This trial is treating patients with pancreatic cancer.

This is a systemic therapy trial that may be followed with surgery.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Investigating the safety and efficacy of NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer, NEO-IMPACT.

Cooperative Group

Australasian Gastro-Intestinal Trials Group (AGITG)


Eligible participants will receive 6 treatment cycles every 2 weeks of combined immuno-chemotherapy (durvalumab with modified FOLFIRINOX). mFOLFIRINOX will be administered as a day patient in hospital, given via intravenous infusion (IV) on day 1 of each cycle. One of the chemotherapy drugs (5-FU) will be given as a continuous infusion over 46 hours via portable pump, so participants will return to hospital on day 3 to have this pump disconnected. Durvalumab will be given via IV on Day 1 of each second cycle. At the end of the 6 treatment cycles, participants will be assessed for their suitability for surgery. After surgery, all participants will then receive an additional 6 treatment cycles of chemotherapy (mFOLFIRINOX) alone.

Recruiting Hospitals Read MoreRead more

Warringal Private Hospital
Yuan Guo
03 9274 1423

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.